R1 RCM - RCM Stock Forecast, Price & News

R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers. The company also provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. The company was founded in 2003 and is headquartered in Murray, Utah.

Wall Street Analyst Weigh In

A number of research firms have issued reports on RCM. Deutsche Bank Aktiengesellschaft raised their target price on R1 RCM from $26.00 to $31.00 in a report on Thursday, August 4th. Guggenheim initiated coverage on R1 RCM in a report on Wednesday, April 13th. They set a "neutral" rating on the stock. JPMorgan Chase & Co. assumed coverage on shares of R1 RCM in a research note on Monday, August 1st. They set an "overweight" rating for the company. Barclays restated an "overweight" rating and set a $29.00 target price on shares of R1 RCM in a research report on Wednesday, June 29th. Finally, TheStreet raised shares of R1 RCM from a "d" rating to a "c" rating in a report on Monday, May 9th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $30.17.

R1 RCM Stock Performance

RCM traded up $0.18 during trading hours on Wednesday, reaching $25.90. The company's stock had a trading volume of 60,114 shares, compared to its average volume of 1,257,141. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.57. The company's 50-day moving average is $22.52 and its 200-day moving average is $23.77. R1 RCM has a 52 week low of $18.71 and a 52 week high of $27.86. The firm has a market cap of $7.24 billion, a PE ratio of 142.90, a price-to-earnings-growth ratio of 6.16 and a beta of 0.91.

R1 RCM (NASDAQ:RCM - Get Rating) last released its quarterly earnings results on Monday, May 9th. The healthcare provider reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). R1 RCM had a return on equity of 12.72% and a net margin of 3.98%. The firm had revenue of $385.70 million for the quarter, compared to analyst estimates of $384.18 million. During the same period in the previous year, the business posted ($2.37) earnings per share. The business's revenue for the quarter was up 12.6% on a year-over-year basis. On average, equities analysts forecast that R1 RCM will post 0.24 EPS for the current year.